Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance.
- NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_assertion description "[We estimated the cumulative incidence of first disease-free survival (DFS) events in the CNS versus other sites by competing risks analysis in patients with HER2-positive early breast cancer who had been randomly assigned to receive 1 year of trastuzumab or to observation in the HERA trial after a median follow-up of 4 years (IQR 3�5-4�8).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance.
- NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_assertion evidence source_evidence_literature NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance.
- NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_assertion SIO_000772 23414588 NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance.
- NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_assertion wasDerivedFrom befree-20140225 NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance.
- NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_assertion wasGeneratedBy ECO_0000203 NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance.
- befree-20140225 importedOn "2014-02-25" NP552787.RArWKvDT4iTu7wXNfG1ITuOIEsRVzjOzGn-EGfCp9t2IY130_provenance.